CN102741696A - 阿尔茨海默病外周细胞中pkc同工酶加工的异常改变 - Google Patents

阿尔茨海默病外周细胞中pkc同工酶加工的异常改变 Download PDF

Info

Publication number
CN102741696A
CN102741696A CN2010800551432A CN201080055143A CN102741696A CN 102741696 A CN102741696 A CN 102741696A CN 2010800551432 A CN2010800551432 A CN 2010800551432A CN 201080055143 A CN201080055143 A CN 201080055143A CN 102741696 A CN102741696 A CN 102741696A
Authority
CN
China
Prior art keywords
pkc
isodynamic enzyme
index
peptide
pkc isodynamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800551432A
Other languages
English (en)
Chinese (zh)
Inventor
T·K·卡恩
D·L·阿尔康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blanchette Rockefeller Neuroscience Institute
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Publication of CN102741696A publication Critical patent/CN102741696A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800551432A 2009-10-02 2010-10-01 阿尔茨海默病外周细胞中pkc同工酶加工的异常改变 Pending CN102741696A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24836109P 2009-10-02 2009-10-02
US61/248,361 2009-10-02
PCT/US2010/051112 WO2011041670A2 (en) 2009-10-02 2010-10-01 Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells

Publications (1)

Publication Number Publication Date
CN102741696A true CN102741696A (zh) 2012-10-17

Family

ID=43302691

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800551432A Pending CN102741696A (zh) 2009-10-02 2010-10-01 阿尔茨海默病外周细胞中pkc同工酶加工的异常改变

Country Status (7)

Country Link
US (1) US20110212474A1 (enExample)
EP (1) EP2483695A2 (enExample)
JP (2) JP6013184B2 (enExample)
CN (1) CN102741696A (enExample)
BR (1) BR112012007557A2 (enExample)
CA (1) CA2776498A1 (enExample)
WO (1) WO2011041670A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115078570A (zh) * 2022-05-30 2022-09-20 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906164A1 (en) * 2013-03-15 2014-09-18 Daniel L. Alkon Methods for identifying neuroprotective pkc activators
JP2018512128A (ja) 2015-03-06 2018-05-17 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病集団を含む集団を分類するための方法
WO2017147114A1 (en) * 2016-02-22 2017-08-31 Blanchette Rockefeller Neurosciences Institute Diagnosing mild cognitive impairment (mci), predicting alzheimer's disease (ad) dementia onset, and screening and monitoring agents for treating mci or preventing dementia onset
US20180282784A1 (en) * 2017-03-31 2018-10-04 NeuroDiagnostics LLC LYMPHOCYTE-BASED PKCe TEST FOR ALZHEIMER'S DISEASE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
CN1795158A (zh) * 2003-05-30 2006-06-28 因德纳有限公司 可用于治疗阿尔茨海默病的化合物和含有它们的制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US20030108956A1 (en) * 1993-05-03 2003-06-12 Alkon Daniel L. Cell tests for Alzheimer's disease
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US6077686A (en) * 1996-02-29 2000-06-20 Mount Sinai Hospital Corporation Shc proteins
WO2001027624A2 (en) * 1999-10-08 2001-04-19 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
AUPR215700A0 (en) * 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
CA2437497A1 (en) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Lipid-associated molecules
KR100960256B1 (ko) 2001-02-27 2010-06-01 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 유사분열 촉진인자-활성화 단백질 키나제 인산화에 근거한 알쯔하이머병 진단
US20040014678A1 (en) * 2001-08-08 2004-01-22 Antonella Favit Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US6897014B2 (en) 2002-02-15 2005-05-24 Fuji Photo Film Co., Ltd. Silver halide photographic light-sensitive material, photographic emulsion, and mercapto group-containing polymer compound used for them
KR100574017B1 (ko) 2003-08-11 2006-04-26 삼성전자주식회사 잉크젯 프린터의 잉크 카트리지
KR101332540B1 (ko) 2005-05-27 2013-11-22 칼 짜이스 에스엠테 게엠베하 광산란 디스크, 그 사용 및 파면 측정 장치
KR20130122630A (ko) * 2005-07-29 2013-11-07 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 ｐｋｃ 억제제와 배합된 ｐｋｃ 활성화제의 장기 기억 향상을 위한 용도
US20090029873A1 (en) * 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
WO2007044094A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
US7595167B2 (en) * 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
KR20090119894A (ko) 2007-02-09 2009-11-20 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 두부 외상-유도된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
CN1795158A (zh) * 2003-05-30 2006-06-28 因德纳有限公司 可用于治疗阿尔茨海默病的化合物和含有它们的制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAVIT A ET AL.: "PKC isoenzymes are differentially affected by low concentrations of soluble beta-amyloid protein in Alzheimer"s disease", 《SOCIETY FOR NEUROSCIENCE ABSTRACTS》 *
FAVIZ A ET AL.: "Alzheimer’s-specific effects of soluble β-amyloid on protein kinase C-α and -γ degradation in human fibroblasts", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115078570A (zh) * 2022-05-30 2022-09-20 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用
CN115078570B (zh) * 2022-05-30 2024-05-28 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用

Also Published As

Publication number Publication date
JP6013184B2 (ja) 2016-10-25
JP2013506844A (ja) 2013-02-28
JP2016197112A (ja) 2016-11-24
WO2011041670A2 (en) 2011-04-07
US20110212474A1 (en) 2011-09-01
BR112012007557A2 (pt) 2017-05-02
CA2776498A1 (en) 2011-04-07
EP2483695A2 (en) 2012-08-08
WO2011041670A3 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
Mollenhauer et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
Lian et al. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex
US6495335B2 (en) Compositions and methods for diagnosing alzheimer's disease
KR101375552B1 (ko) 알츠하이머병-특이적 분자 생체 지표(ａｄｓｍｂ)로서 ｅｒｋ1/ｅｒｋ2 포스포릴화비의 알츠하이머병-특이적 변화
Guadagna et al. Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia
US20210270847A1 (en) Protein and peptide biomarkers for traumatic injury to the central nervous system
JP2016197112A (ja) アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化
EP2591367B1 (en) Method for diagnosis
KR20190110927A (ko) 퇴행성 신경질환 진단용 조성물
JP2008520203A (ja) アルツハイマー病の診断および治療のためのホスファターゼ２ａ（ｐｐ２ａ）の異常
US9128104B2 (en) FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
US20080076140A1 (en) Biomarkers of Alzheimer's Disease
Patel et al. Neuronal pentraxin 2 correlates with neurodegeneration but not cognition in idiopathic normal pressure hydrocephalus (iNPH)
Racchi et al. Bradykinin-induced amyloid precursor protein secretion: a protein kinase C-independent mechanism that is not altered in fibroblasts from patients with sporadic Alzheimer's disease
JP2011516883A (ja) Ｅｒｋ１／ｅｒｋ２のリン酸化比のアルツハイマー病特異的な変化―アルツハイマー病に特異的な分子バイオマーカー（ａｄｓｍｂ）
RU2741227C1 (ru) Способ диагностики черепно-мозговой травмы с использованием белковых биомаркеров
RU2538644C1 (ru) Способ прогнозирования развития острого панкреатита после операций на органах брюшной полости
Alagendran et al. Chromogranin A in human saliva as putative biomarker of alzheimer’s type dementia
Alamri Clinical and synaptosomal studies of cannabinoid receptor 1 and presynaptic proteins in the elderly
EARLY et al. PROLONGED LOCAL PARTIAL OXYGEN PRESSURE RESPONSE TO ISCHEMIC FOREARM EXERCISE TEST IN MIGRAINE PATIENTS
Foulds A Study of α-Synuclein, Parkin and TDP-43; Proteins Implicated in Neurodegenerative Disease
Chen et al. P4-166 Overexpression of CDK-5 induces hyperphosphorylation of cytoskeletal proteins and impairment of axonal transport in N2A cells
KR20070084247A (ko) 알츠하이머 질환의 진단 및 치료를 위한 포스파타제 2ａ(ｐｐ2ａ)의 비정상

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121017